Clinical Trial Update: A Study of PC786 to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of Multiple Doses in an RSV Challenge Study [Phase 1, Phase 2]

View source ↗

Summary

Completed Phase 1/2 study evaluating antiviral activity, safety, and pharmacokinetics of multiple doses of PC786 in an RSV challenge model.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infections

Drugs mentioned

• PC786 (PC786)

Snippet

Sponsor: Pulmocide Ltd | Conditions: Respiratory Syncytial Virus Infections | Phase 1, Phase 2 | Status: COMPLETED